News and Announcements
MedAdvisor Partners with Asthma Australia
- Published November 29, 2016 4:02PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
29th November 2016, ASX Announcement
- MedAdvisor partners with Asthma Australia, Australia’s peak body supporting people with asthma and their carers
- Partnership aims to improve health outcomes for the estimated 2.4 million (1 in 10) Australians living with asthma, via the MedAdvisor platform
- High priority health cost reduction area: total cost of asthma in Australia is estimated to be $28 billion per annum with $1.1 billion directly related to productivity costs
- Further builds on MedAdvisor’s health association partnerships that play a key role in driving patient awareness of MedAdvisor
- In line with the Company’s strategy to enhance health outcomes for the 11m Australians living with chronic conditions and lower costs associated with poor medication adherence
MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence company, is pleased to announce it has entered into a partnership with not-for-profit health association Asthma Australia. The partnership will run for an initial period of 12 months.
To view the full announcement, please click on the button below.